Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew N Phillips

Showing results (51-60 of 287) with videos related to

Pageof 29
Sort By:
The Journal of Infectious Diseases|December 4, 2012
Factors associated with adherence amongst 5295 people receiving antiretroviral therapy as part of an international trialJemma L O'Connor, Edward M Gardner, Sharon B Mannheimer, et al.
The Journal of Infectious Diseases|March 23, 2017
Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub-Saharan AfricaAndrew N Phillips, John Stover, Valentina Cambiano, et al.
BMC Cancer|June 6, 2026
Early antiretroviral therapy and long-term cancer risk in HIV: 9-year outcomes from the START randomized trialRamya Ramaswami, Jacqueline A Nordwall, Duncan Gilbert, et al.
The Journal of Infectious Diseases|December 16, 2017
Serum Albumin as a Prognostic Marker for Serious Non-AIDS Endpoints in the Strategic Timing of Antiretroviral Treatment (START) StudyAndreas Ronit, Shweta Sharma, Jason V Baker, et al.
Journal of the International AIDS Society|February 27, 2025
Rapid development of an online tracker to communicate the human impact of abruptly halting PEPFAR supportBrooke E Nichols, Elvin H Geng, Eric Moakley, et al.
The Journal of Infectious Diseases|July 9, 2018
Chronic Kidney Disease Risk in African and Caribbean Populations With HIVSophie Jose, Lisa Hamzah, Rachael Jones, et al.
Antiviral Therapy|January 30, 2003
Analysis of virological efficacy in trials of antiretroviral regimens: drawbacks of not including viral load measurements after premature discontinuation of therapyOle Kirk, Court Pedersen, Matthew Law, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 21, 2004
Use of viral load measured after 4 weeks of highly active antiretroviral therapy to predict virologic outcome at 24 weeks for HIV-1-positive individualsColette J Smith, Schlomo Staszewski, Caroline A Sabin, et al.
The American Journal of Gastroenterology|June 30, 2005
Decline in esophageal candidiasis and use of antimycotics in European patients with HIVAmanda Mocroft, Cristina Oancea, Jan van Lunzen, et al.
AIDS (London, England)|May 24, 2013
CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral useAmanda Mocroft, Andrew N Phillips, Jose Gatell, et al.
Pageof 29

Showing results (51-60 of 287) with videos related to

Sort By:
Pageof 29
The Journal of Infectious Diseases|December 4, 2012
Factors associated with adherence amongst 5295 people receiving antiretroviral therapy as part of an international trialJemma L O'Connor, Edward M Gardner, Sharon B Mannheimer, et al.
The Journal of Infectious Diseases|March 23, 2017
Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub-Saharan AfricaAndrew N Phillips, John Stover, Valentina Cambiano, et al.
BMC Cancer|June 6, 2026
Early antiretroviral therapy and long-term cancer risk in HIV: 9-year outcomes from the START randomized trialRamya Ramaswami, Jacqueline A Nordwall, Duncan Gilbert, et al.
The Journal of Infectious Diseases|December 16, 2017
Serum Albumin as a Prognostic Marker for Serious Non-AIDS Endpoints in the Strategic Timing of Antiretroviral Treatment (START) StudyAndreas Ronit, Shweta Sharma, Jason V Baker, et al.
Journal of the International AIDS Society|February 27, 2025
Rapid development of an online tracker to communicate the human impact of abruptly halting PEPFAR supportBrooke E Nichols, Elvin H Geng, Eric Moakley, et al.
The Journal of Infectious Diseases|July 9, 2018
Chronic Kidney Disease Risk in African and Caribbean Populations With HIVSophie Jose, Lisa Hamzah, Rachael Jones, et al.
Antiviral Therapy|January 30, 2003
Analysis of virological efficacy in trials of antiretroviral regimens: drawbacks of not including viral load measurements after premature discontinuation of therapyOle Kirk, Court Pedersen, Matthew Law, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 21, 2004
Use of viral load measured after 4 weeks of highly active antiretroviral therapy to predict virologic outcome at 24 weeks for HIV-1-positive individualsColette J Smith, Schlomo Staszewski, Caroline A Sabin, et al.
The American Journal of Gastroenterology|June 30, 2005
Decline in esophageal candidiasis and use of antimycotics in European patients with HIVAmanda Mocroft, Cristina Oancea, Jan van Lunzen, et al.
AIDS (London, England)|May 24, 2013
CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral useAmanda Mocroft, Andrew N Phillips, Jose Gatell, et al.
Pageof 29